Myesha Lacy
Investor Relations Contact chez ARCELLX, INC.
Profil
Myesha Lacy is currently the Vice President-Investor Relations at Arcellx, Inc. She previously worked as the Director-Investor Relations & Communications at Hyperion Therapeutics, Senior Director-Investor Relations at ZS Pharma, Vice President-Investor Relations & Communications at Global Blood Therapeutics, and Vice President-Investor Relations & Communications at Adverum Biotechnologies.
She completed her undergraduate degree at Holy Names University.
Postes actifs de Myesha Lacy
| Sociétés | Poste | Début |
|---|---|---|
| ARCELLX, INC. | Investor Relations Contact | 01/06/2021 |
Anciens postes connus de Myesha Lacy
| Sociétés | Poste | Fin |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Investor Relations Contact | - |
| ZS PHARMA INC | Investor Relations Contact | - |
| HYPERION THERAPEUTICS INC | Investor Relations Contact | - |
| GLOBAL BLOOD THERAPEUTICS, INC. | Investor Relations Contact | - |
Formation de Myesha Lacy
| Holy Names University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ARCELLX, INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
